Fasudil Hydrochloride Hydrate

盐酸法舒地尔

Report date: 2025/01/09 16:41:41
NME

Base Information

Drug NameFasudil Hydrochloride Hydrate
Drug Alias Name水合盐酸法舒地尔ChuanweiFasudilumEril Injection SFasdil +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRho-associated protein kinase 1 inhibitorsRho-associated protein kinase 2 inhibitorsProtein kinase C inhibitors
TargetsRho-associated protein kinase 1Rho-associated protein kinase 2Protein kinase C
Therapy Area/IndicationsCorticobasal degenerationCognitive DysfunctionHypercholesterolemia +[15] 
Global Approved IndicationsVasospasm, IntracranialBrain Ischemia
Approved Indications in ChinaVasospasm, IntracranialBrain Ischemia
Original Approved Country/TerritoryJapan
Original Approved Date1995/06/30
Country/TerritoryUnited StatesNorwayGermany +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAsahi Kasei Corp
China Registration ClassN/A

Develop Information

Active CompaniesZhongda Hospital Affiliated To Southeast UniversityUniversity Of ExeterAsahi Kasei Pharma America Corp +[5] 
Inactive CompaniesColorado State UniversityThe Brigham and Women's HospitalShahid Beheshti University Of Medical Sciences +[5] 
Active IndicationsCognitive DysfunctionAlzheimer DiseaseVasospasm, Intracranial +[6] 
Inactive IndicationsCorticobasal degenerationHypercholesterolemiaScleroderma, Systemic +[9] 

Other Information

ATC CodeC04AX32
Related LinksWikipediaDrugBankKEGG